Vistagen Therapeutics Inc. ((VTGN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vistagen Therapeutics Inc. is conducting a Phase 2 clinical trial titled A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder. The study aims to evaluate the effectiveness and safety of Fasedienol Nasal Spray in alleviating anxiety symptoms induced by public speaking challenges in adults with Social Anxiety Disorder. This research is significant as it explores a potential new treatment option for a condition that affects many individuals worldwide.
The intervention being tested is Fasedienol Nasal Spray, an intranasal drug designed to provide quick relief from acute anxiety symptoms. The study involves administering either a single or repeat dose of the nasal spray to participants, with the goal of reducing anxiety during public speaking situations.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. It involves triple masking, meaning that the participants, investigators, and outcomes assessors are unaware of which treatment the participants receive. The primary purpose of the study is treatment-focused.
The study began on January 29, 2025, and the latest update was submitted on October 22, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.
The market implications of this study update could be significant for Vistagen Therapeutics Inc. A successful outcome may enhance the company’s stock performance and positively influence investor sentiment. In the broader industry context, this trial could position Vistagen as a leader in developing innovative treatments for anxiety disorders, potentially impacting competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.